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Abstract 
Background: Acute respiratory distress syndrome, which is caused by acute lung injury, is a destructive respiratory 
disorder caused by a systemic inflammatory response. Persistent inflammation results in irreversible alveolar fibrosis. 
Because hydrogen gas possesses anti-inflammatory properties, we hypothesized that daily repeated inhalation of 
hydrogen gas could suppress persistent lung inflammation by inducing functional changes in macrophages, and con-
sequently inhibit lung fibrosis during late-phase lung injury.
Methods: To test this hypothesis, lung injury was induced in mice by intratracheal administration of bleomycin 
(1.0 mg/kg). Mice were exposed to control gas (air) or hydrogen (3.2% in air) for 6 h every day for 7 or 21 days. Respira-
tory physiology, tissue pathology, markers of inflammation, and macrophage phenotypes were examined.
Results: Mice with bleomycin-induced lung injury that received daily hydrogen therapy for 21 days (BH group) 
exhibited higher static compliance (0.056 mL/cmH2O, 95% CI 0.047–0.064) than mice with bleomycin-induced lung 
injury exposed only to air (BA group; 0.042 mL/cmH2O, 95% CI 0.031–0.053, p = 0.02) and lower static elastance (BH 
18.8  cmH2O/mL, [95% CI 15.4–22.2] vs. BA 26.7  cmH2O/mL [95% CI 19.6–33.8], p = 0.02). When the mRNA levels of 
pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 
were significantly lower in the BH group than in the BA group. There were significantly fewer M2-biased macrophages 
in the alveolar interstitium of the BH group than in the BA group (3.1% [95% CI 1.6–4.5%] vs. 1.1% [95% CI 0.3–1.8%], 
p = 0.008).
Conclusions: The results suggest that hydrogen inhalation inhibits the deterioration of respiratory physiological 
function and alveolar fibrosis in this model of lung injury.
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Introduction
Excessive, non-specific inflammation in the lungs initi-
ates pathological processes leading to acute lung injury 
(ALI) and acute respiratory distress syndrome (ARDS), 
which directly and indirectly cause destruction of lung 
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tissue including alveolar structures [1]. The develop-
ment of ARDS is triggered by an immune response that 
leads to activation of classically activated macrophages, 
or M1 macrophages, and accumulation of neutrophils 
in the alveoli. As a result, alveolar epithelial cells and 
vascular endothelial cells are extensively damaged, 
and pulmonary edema develops (exudation phase) [2, 
3]. Seven to 10  days after onset, proliferation of type 
II alveolar epithelial cells and fibroblasts is observed 
in the destroyed alveoli (proliferative phase) [1]. This 
process of reconstruction is accompanied by persis-
tent inflammation can promote alveolar fibrosis and 
decrease alveolar compliance (fibrotic phase). Alter-
natively activated macrophages, or M2 macrophages, 
which differentiate as a result of persistent inflamma-
tion, play a key role in promoting disordered alveo-
lar fibrosis [3]. Overexpression and persistence of M2 
macrophages in the alveolar interstitium is a hallmark 
of the transition to the fibrotic phase [2, 4]. Therefore, 
novel therapies to reduce persistent inflammation prior 
to the establishment of irreversible alveolar fibrosis are 
required and have attracted great interest.
Molecular hydrogen has potent antioxidant and 
anti-inflammatory properties [5, 6]. The mechanisms 
underlying the anti-inflammatory effects of hydrogen 
are becoming clearer with known inhibition of proin-
flammatory cytokines and upstream signaling molecule 
[7–9]. Previous studies using animal models suggest 
that hydrogen may ameliorate hyperoxic lung injury, 
ovalbumin-induced asthma, and anti-type II collagen 
antibody-induced arthritis (a model for human rheu-
matoid arthritis) by inhibiting inflammatory signaling 
by the innate immune system and regulating signaling 
cascades that impact macrophages [7, 8, 10]. Inhala-
tion of hydrogen gas may be a straightforward and 
promising therapeutic option because inhaled gaseous 
molecules can directly reach the alveoli. Additionally, 
inhaled hydrogen has a low chemical toxicity [11, 12]. 
Thus, this gaseous therapy has good clinical feasibility, 
as long as its flammability can be controlled.
A recent investigation demonstrated that hydro-
gen inhalation suppressed increases in oxidative stress 
and inflammation induced by intratracheal bleomycin 
administration in mice and suppressed the malignant 
cycle toward lung fibrosis initiated by transforming 
growth factor (TGF)-β1 and inflammation [13]. In the 
current study, we sought to expand on those findings 
and assessed lung physiology using basal respira-
tory function parameters in the same well-established 
mouse model of ARDS [14, 15]. Additionally, we exam-
ined the upstream mechanisms mediating the pro-




Eight-week-old, C57BL/6 male mice (21–23  g, specific-
pathogen free) were purchased from CLEA Japan Inc 
(Tokyo, Japan). Mice were kept on a 12-h light/dark cycle 
at 20 to 22 °C and fed sterile food and water. Every effort 
was made to minimize the number of experimental ani-
mals and minimize pain or distress during the experi-
mental procedures. All protocols followed the principles 
of laboratory animal care (NIH Publication No. 86-23, 
revised 1985), and all research protocols were reviewed 
and approved by the Animal Care and Use Committee, 
Okayama University (OKU-2018876). This study was 
conducted in compliance with the ARRIVE guidelines 
(https:// arriv eguid elines. org/). Animal condition was 
checked twice daily after the administration of bleo-
mycin. Dying animals that met humane endpoint were 
euthanized by  CO2 asphyxiation and were excluded from 
the analysis. Before scheduled sampling, animals were 
sacrificed by exsanguination under deep anesthesia with 
intraperitoneal administration of 0.75  mg/kg medeto-
midine hydrochloride (Domitor, Meiji Seika Pharma, 
Tokyo, Japan), 4 mg/kg midazolam (Dormicum, Astellas 
Pharma, Tokyo, Japan), and 5 mg/kg butorphanol (Vetor-
phale, Meiji Seika) as previously described [16]. All lobes 
of the right lung were removed en bloc, snap-frozen using 
liquid nitrogen, and stored at − 80 °C until use. Then, the 
right lungs were divided, placed in liquid nitrogen, and 
ground into a powder. Powdered lung tissue (30 mg) was 
used for RNA extraction for RT-PCR or protein extrac-
tion for Western blot. The left lung was used for histo-
pathological analysis.
Generation of bleomycin‑induced lung injury model 
and inhalation of hydrogen gas
This study was conducted using a well-established 
mouse model of lung injury and idiopathic pulmonary 
fibrosis [15, 17]. In summary, lung injury was generated 
by administrating bleomycin (bleomycin hydrochlo-
ride, Nippon Kayaku, Tokyo, Japan) dissolved in saline 
intratracheally via tracheotomy [17]. The bleomycin 
causes persistent inflammation pharmacologically in 
the bronchus and alveoli, eventually resulting in alveo-
lar fibrosis. Mice were anesthetized, and an incision was 
made through the neck into the front of trachea. Bleomy-
cin dissolved in saline (50 µL, 1 mg/kg) was injected using 
a Hamilton syringe and a 32G needle, then the wound 
was closed by cyanoacrylate glue. In sham controls, 
saline without bleomycin was administrated in the same 
manner. We conducted a preliminary pathologic assess-
ment, which confirmed that bleomycin administration 
induced lung injury with temporal changes in pathology 
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that mimicked those observed during ALI/ARDS (Addi-
tional file 1: Fig. S1).
Mice were randomly assigned to 1 of 4 experimental 
groups: (1) saline administration and air inhalation (SA 
group), (2) saline administration and hydrogen inhala-
tion (SH group), (3) bleomycin administration and air 
inhalation (BA group), and (4) bleomycin administra-
tion and hydrogen inhalation (BH group). A gas cylinder 
containing 4% hydrogen and 96% nitrogen blended gas 
was prepared (Taiyo Nissan, Tokyo, Japan). By mixing 
800 mL/min of the 4%  H2/96%  N2 mixture and 200 mL/
min of 100%  O2 gas, a final mixture of 3.2%  H2, 20%  O2 
and 76.8%  N2 gas, delivered at 1  L/min, was generated. 
Air for the control group is created by mixing 800  mL/
min of 100%  N2 gas and 200  mL/min of 100%  O2 gas. 
For gas administration, 5 or fewer mice were placed 
in a sealed acrylic box (L 40 cm × W 20 cm × H 20 cm) 
for mixed gas exposure while temperature (acceptable 
range 22–24 °C) and humidity (acceptable range 40–70%) 
were monitored. Mice were exposed to either air or 3.2% 
hydrogen in air for 6 h every day for either 7 or 21 days 
(Additional file 2: Table S1).
Respiratory physiological examination
The respiratory physiology was evaluated using a 
 FlexVent® small animal ventilator with spirometer 
(SCIREQ, Montreal, PQ, Canada). The programs for 
examination of respiratory function were already pro-
grammed into the device and were performed accord-
ing to the manufacturer’s instructions. Mice were 
anesthetized as described above, and 1 cm of a 18-gauge 
endotracheal tube was inserted into the trachea by tra-
cheostomy. The endotracheal tube was attached to the 
FlexVent. Then, mechanical ventilation is started at 150 
respirations per minute, 10 mL/kg of tidal volume, and an 
inspiratory:expiratory ratio of 2:3 for 1  min. Inspiratory 
capacity (IC) was measured in mL using the “Deep Infla-
tion” program where the lung was inflated with 27  cm 
 H2O of inspiratory pressure. The static compliance (Cst) 
in mL/cm  H2O and the static elastance (Est) in cm  H2O/
mL were measured using the “PVs-V” program, where 
the lungs were inflated stepwise with 40 mL/kg of venti-
lation volume. Cst and Est were calculated by computer 
analysis according to the pressure–volume (PV) loop 
curve created. Total respiratory system resistance (Rs) 
was measured using the “SnapShot-150” program, where 
3 repetitions of sine-wave-pressure forced ventilation 
(1.2  s, 2.5  Hz) were performed. The protocol consisted 
of 1 min of mechanical ventilation, 1 cycle of deep infla-
tion, and three 1-min cycles of mechanical ventilation 
using the Deep Inflation, the PVs-V, and finally the Snap-
Shot-150 programs. IC, Cst and Est were calculated as 
the median of the three individual measurements.
Computed tomography
The lung computed tomography (CT) images were 
taken using a small-animal CT system, Latheta 
 LCT200® (Hitachi, Ltd. Tokyo. JAPAN). The mice are 
sedated, then inserted into the CT machine and imaged 
with the following settings: Imaging condition, lung; 
Pixel size, 48  μm; Slice thickness, 192  μm; Slice inter-
val, 192 μm; X-ray voltage, Low; Scale of tomographic 
image, − 700 to + 100; and Respiratory synchroniza-
tion, “Yes”. Of the 70 slices taken of the whole lung field, 
40 slices in the center were used for analysis.
After the CT images were saved as JPG files, images 
of the inside of the thorax were extracted and con-
verted to 8-bit grayscale. ImageJ (National Institutes of 
Health, Bethesda, Maryland) was used for subsequent 
image analysis. To trace the areas in the lung contain-
ing air, the “Threshold” program was set at “Range: 
0–136”. To measure the area, the following settings in 
“Analyze Particles” program were used: Size (inch^2), 
0 -Infinity; Circularity 0.00–1.00; and Show Bare Out-
line (the obtained area value was defined as A). When 
this area value A included components which should 
be excluded, such as pulmonary vessels, a correction 
was performed. To calculate the area value of the com-
ponents to be excluded, the "Threshold" program with 
Range "137–255" and "Analyze Particles" program with 
Size (inch^2), 0–Infinity; Circularity 0.00–1.00; Show 
Bare Outline was used, and the obtained area value was 
defined as B. The area obtained by subtracting B from A 
was the true air-containing region. The air-containing 
capacity of the whole lung field was calculated by inte-
grating the slice width and the area containing air as 
detected above.
Hematoxylin and eosin and elastica masson staining
The left lung was fixed with 4% paraformaldehyde dis-
solved in phosphate buffered saline (PBS) for 2  days, 
embedded in paraffin, then sliced into 4-µm sections. 
Hematoxylin and eosin (HE) staining and Elastica Mas-
son (EM) staining were performed using standardized 
protocols by skilled technicians in the Central Research 
Laboratory at Okayama University. Images were auto-
matically captured using the Nano-Zoomer 2.0RS slide 
scanner (Hamamatsu Photonics, Shizuoka, Japan) and 
analyzed using NDP.view2 software, (Hamamatsu Pho-
tonics, Shizuoka, Japan). Twenty high-magnification 
images (total magnification 400×) of HE-stained tis-
sue were captured randomly from one slice, and evalu-
ated using the Lung Injury Score [18] to quantitate the 
extent of histologic lung injury and the Ashcroft Score 
[19] to quantitate fibrosis.
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SYBR Green 2‑step real‑time reverse transcriptase 
polymerase chain reaction
Messenger RNA levels for interleukin (IL)-6, IL-4, IL-10, 
IL-13, collagen type I, fibronectin, and ribosomal protein 
L4 (RPL4) were assessed using SYBR Green, 2-step, real-
time, reverse-transcription PCR. RNA extraction was 
performed with the  Nucleospin® RNA kit (Takara Bio 
Inc., Kusatsu, Japan) using powdered lung tissue (30 mg) 
according to the manufacturer’s instruction. Total RNA 
(1 μg) was reverse transcribed with  ReverTraAce® qPCR 
RT Master Mix (TOYOBO Inc., Osaka, Japan). The mix-
ture for SYBR Green PCR was prepared using THUN-
DERBIRD SYBR qPCR MIX (TOYOBO Inc., Osaka, 
Japan) and primers (Additional file 2: Table S2). The ther-
mal cycling protocol activated the polymerase for 10 min 
at 95  °C, followed by 40 cycles of 95  °C for 15  s, and 
60 °C for 1 min in a StepOnePlus Realtime PCR machine 
(Thermo Fisher Scientific, Waltham, Massachusetts).
Bronchoalveolar lavage fluid assays
Bronchoalveolar lavage fluid (BALF) was collected by 
injecting 1 mL of PBS into the trachea, flushing it in and 
out 5 times, and then collecting the fluid. After centrifug-
ing at 500 × g at 4 °C, the supernatant was collected, and 
the total protein concentration was measured via bicin-
choninic acid (BCA) assay using the Pierce BCA Protein 
Assay Kit (Thermo Scientific, Waltham, Massachusetts). 
Turk’s staining solution (200 μL, Nakarai tesque, Kyoto, 
Japan) was added to the precipitate to stain leukocytes, 
and the cells were counted using a Burker-Turk counter. 
To examine IL-6 expression in alveolar macrophages, 
RT-PCR of BALF cells was performed. Cells were col-
lected by centrifugation from BALF, re-suspended in 
the lysis buffer included in the Nucleospin  XS® RNA kit 
(Takara Bio Inc., Kusatsu, Japan), and immediately frozen 
by liquid nitrogen. Then, RNA was extracted according 
to the manufacturing instructions. The amount of total 
RNA was 70–100 ng per sample. cDNA was obtained by 
reverse transcription with  ReverTraAce® qPCR RT Mas-
ter Mix, and real-time PCR for IL-6 was performed.
Western blotting
Powdered frozen graft tissue (30  mg) was mixed with 
300 μL of radioimmunoprecipitation assay (RIPA) buffer, 
which is consisted of 50 mM Tris–HCl (pH 8.0), 150 mM 
NaCl,1%  Igepal® CA-630 (Merck, Darmstadt, Germany), 
0.5% Sodium deoxycshoate, 0.1% sodium dodecyl sulfate 
(SDS) and 1 mM EDTA, and cOmplete™ Mini Protease 
Inhibitor Cocktail (Merck. Darmstadt, Germany). After 
homogenizing and measuring the protein concentration, 
samples were further dissolved in SDS-PAGE sample 
buffer (62.5 mM Tris–HCl pH 6.8, 10% glycerol, 2% SDS, 
bromophenol blue) to 1 μg/μL.
For the analysis of collagen type I (COL1), fibronectin 
and α-smooth muscle actin (αSMA), proteins (10  μg) 
from lung tissue were separated by electrophoresis on 
8% acrylamide gels without SDS and transferred to 
 Immobilon®-P polyvinylidene difluoride (PVDF) mem-
brane (0.45  µm) (Merck, Darmstadt, Germany). For the 
analysis of TGFβ, proteins (10 μg) from lung tissue were 
separated by electrophoresis on 12% acrylamide, 0.1% 
SDS gels.
PVDF membranes are blocked with 5% non-fat dry 
milk to prevent non-specific binding of antibodies. Pri-
mary antibody against fibronectin, αSMA, COL1, and 
TGFβ were diluted with Can Get Signal immunoreaction 
enhancer solution 1 (Toyobo, Osaka, Japan) (Additional 
file 2: Table S3), and incubated with the membranes over-
night at 4  °C. Horseradish-peroxidase–conjugated sec-
ondary antibodies against mouse IgG and rabbit IgG were 
diluted with Can Get Signal immunoreaction enhancer 
solution 2 (Toyobo, Osaka, Japan) and membranes were 
incubated for 2  h at room temperature. Chemilumines-
cence detection was performed with ECL Prime Western 
Blotting Detection Reagents (Cytiva, Tokyo, Japan) and a 
WSE-6100 LuminoGraph I (ATTO Corporation, Tokyo, 
Japan).
Immunohistochemistry
Paraffin-embedded lung tissue sections  (4  µm) were 
immunostained for TGF-β and IL-6 using an ABC Kit 
(Vector laboratories INC., Burlingame, California). 
Information on the primary and secondary antibodies 
used is provided in Additional file 2: Table S3. Sections 
were deparaffinized, rehydrated, and treated for antigen 
retrieval with 10  mM citric acid pH 6.0 at 120  °C for 
10  min in a pressure cooker. Endogenous peroxidase 
inhibition was performed with 0.3% hydrogen perox-
ide in PBS for 20  min at room temperature. Blocking 
treatment was performed with 10% goat serum in tris 
buffered saline with 0.1% Tween 20 (TBS-T) to prevent 
non-specific binding of antibodies. The primary anti-
bodies were diluted by Can Get Signal immunostain-
ing Solution A (Toyobo, Osaka, Japan), applied to the 
sections, incubated overnight at 4 °C, and then washed 
with TBS-T. Biotin-conjugated secondary antibodies 
were diluted by Can Get Signal immunostaining Solu-
tion A, applied on the sections, and incubated for 2  h 
at room temperature. After washing, ABC reagent was 
applied to the sections then incubated for 30  min at 
room temperature as per the manufacturer’s instruc-
tions. For 3,3′-diaminobenzidine (DAB) staining, one 
DAB tablet (10  mg per tablet, FUJIFILM Wako Pure 
Chemical Corporation, Osaka, Japan) was dissolved in 
50  mL of 0.05  mol/L Tris–HCl buffer pH 7.6 with 10 
μL of 30% hydrogen peroxide as per the manufacturer’s 
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instructions. Sections were incubated in DAB solution 
for 10  min at room temperature, then washed under 
running water, counterstained with hematoxylin, dehy-
dration, clearing, and coverslipping.
Immunofluorescence
Paraffin blocks were sectioned, deparaffinized, rehy-
drated, and treated for antigen retrieval using the 
technique described above. The multiplex fluores-
cent immunostaining was used for staining with anti-
ionized calcium binding adaptor molecule 1 (Iba-1) 
antibody and anti-CD163 antibody. Information on pri-
mary and secondary antibodies is provided (Additional 
file  2: Table  S3). Blocking treatment was performed 
with Super  Block® (SCY AAA125, Cosmo Bio Co., Ltd. 
Tokyo, Japan). Anti-Iba-1 antibody and anti-CD163 
antibody were diluted in Can Get Signal immunostain-
ing Solution A, then incubated on the tissue section 
overnight at 4  °C. After washing, the sections were 
incubated with fluorescently labeled secondary anti-
bodies with Alexa Flour (AF) 488 or 594. DAPI-Fluo-
romount  G® (0100-20, SouthernBiotech, Birmingham, 
AL) was used for nuclear staining and sealing.
Fluorescent images were taken by the Mantra™ 
Quantitative Pathology Imaging System (PerkinElmer 
Inc., Waltham, Massachusetts), and cells were counted 
in the alveoli and interstitium were automatically using 
the  InForm® 2.4.10 software (Akoya Biosciences, Inc., 
Menlo Park, California). Three images were taken ran-
domly from each section with a 200× image. Fluores-
cence imaging was performed at 488  nm, and 594  nm 
wavelengths. In the InForm software, a computer learn-
ing system was used to learn the characteristics of 
alveolar epithelium and alveolar interstitum tissues and 
exclude tracheal epithelial cells. The cells were identi-
fied by DAPI staining, and the immunostaining was 
visualized at 488 nm (Iba-1) or 594 nm (CD163) wave-
length. The intensity thresholds for Iba-1-positive and 
CD163-positive cells were carefully adjusted and iden-
tified, and all images were analyzed according to the 
same rules.
Statistics
Statistical analysis was performed using IBM SPSS Statis-
tics version 23.0 (IBM, Armonk, New York). Statistically 
significant differences between groups were determined 
using an unpaired two-tailed Student’s t-test for single 
comparisons; the Kruskal–Wallis test followed by Dunn’s 
multiple comparison test for multiple comparisons. All 
values are presented as mean ± 95% confidence interval 
(CI). Results were considered significant at p < 0.05.
Results
Hydrogen inhalation for 21 days mitigates respiratory 
physiological dysfunction during fibrotic phase 
after bleomycin‑induced lung injury
While IC and Rs were not significantly different between 
mice that received hydrogen therapy and mice that 
received sham/air therapy (BH group vs. BA group, 
Fig. 1a, b) when we examine respiratory physiology, Cst, 
an index of the distensibility of the respiratory system, 
was significantly higher in mice that received hydrogen 
therapy (BH 0.056  mL/cm  H2O [95% CI 0.47–0.64] vs. 
BA 0.042  mL/cm  H2O [95% CI 0.031–0.053], p = 0.02) 
(Fig. 1c). The Est of the lungs in mice that received hydro-
gen therapy after lung injury was significantly lower than 
in mice with air therapy (BH 18.8 cm  H2O/mL [95% CI 
15.4–22.2] vs. BA 26.7 cm  H2O/mL [95% CI 19.6–33.8], 
p = 0.02) (Fig.  1d). In fibrotic phase after lung injury, 
fibrotic changes progress in the alveolar interstitum, and 
the lung tissues become hardened. These results suggests 
that hydrogen inhalation therapy preserved the ability of 
the lung to expand and reduced lung stiffness. There were 
no differences in any of the respiratory parameters exam-
ined between hydrogen and sham/air therapy when lung 
injury was not induced (SH and SA groups), suggesting 
that hydrogen has no effects on respiratory physiological 
function in individuals without alveolar damage (Fig. 1).
Hydrogen inhalation for 21 days can attenuate 
the reduction in lung capacity typical 
of bleomycin‑induced lung injury
Although bleomycin-induced lung injury significantly 
reduced aerated lung capacity as determined using CT 
volumetry (BA group), hydrogen treatment for 21  days 
significantly ameliorated this reduction as indicated by 
higher aerated lung capacities in BH group than those in 
the BA group (BH 269 μL [95% CI 228–309] vs. BA 193 
μL [95% CI 139–248], p = 0.02). Hydrogen treatment had 
no effect on aerated lung capacity in the absence of lung 
injury (SH and SA groups) (Fig. 2a, b).
Hydrogen inhalation for 21 days reduced alveolar fibrosis 
after bleomycin‑induced lung injury
There were many cytoplasm-rich cells, which might 
include fibroblasts, myofibroblasts, and inflammatory 
cells, in the alveolar interstitium in lungs with bleomy-
cin-induced lung injury. The presence of these cells in 
the alveolar interstitium was attenuated by hydrogen 
treatment (BH group) (Fig.  3a, H&E staining). Collagen 
bundles were seen in the interstitium of the mice with 
bleomycin-induced lung injury (BA group) and were less 
frequently observed in mice treated with hydrogen for 
21 days (BH group) (Fig. 3a, E-M). Lung injury scores of 
the lungs of mice in the BA and BH groups were as low 
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as 0.12, and no statistically significances differences were 
seen between the treatment groups (Fig.  3b). Ashcroft 
score, which quantitated the extent of fibrosis, demon-
strated that there were more fibrotic changes in the lungs 
of mice in the BA group compared with the BH group 
(Fig. 3c).
Hydrogen inhalation for 21 days inhibited increases 
in fibronectin protein expression after bleomycin‑induced 
lung injury
Expression of COL1 and αSMA did not differ between 
any of the treatment groups at the 21-day timepoint. 
(Fig.  4a, Additional file  1: Fig. S2, Additional file  3). 
Fibronectin was more highly expressed after bleomy-
cin-induced lung injury in the BA group than in the 
SA group (BA 0.371 [95% CI 0.314–0.428] vs. SA 0.212 
[95% CI 0.143–0.281], p = 0.004), and hydrogen therapy 
showed a tendency to reduce this upregulation, though 
the differences in protein levels did not reach statistical 
significance (BH 0.294 [95% CI 0.245–0.343] vs. BA 0.371 
[95% CI 0.314–0.428], p = 0.069) (Fig. 4b).
Hydrogen inhalation for 7 days attenuates 
the upregulation of critical interleukins and downregulates 
fibronectin mRNA in lung tissue after bleomycin‑induced 
lung injury
To begin to discern the mechanisms underlying hydro-
gen’s protective effects in reducing fibrosis in this ani-
mal model, we examined the inflammatory response 
7  days after lung-injury induction. Expression of the 
mRNAs for IL-6, IL-4 and IL-13, all of which are con-
sidered pro-inflammatory cytokines in the lung, were 
significantly upregulated 7  days after bleomycin admin-
istration as compared with saline-treated control lungs. 
Repeated hydrogen inhalation significantly suppressed 
upregulation of IL-6, IL-4 and IL-13 in response to ble-
omycin-induced lung injury (Fig. 5a, b, c). There was no 
statistical difference in IL-10 mRNA expression between 
Fig. 1 The results of respiratory physiological examination of respiratory function during the fibrotic phase of bleomycin-induced lung injury. 
a Inspiratory capacity (IC). b Total respiratory system resistance (Rs). There were no differences in Rs among the four groups (p = 0.51). c Static 
compliance (Cst). d Static elastance (Est). The BA and BH groups had lower IC and Cst and higher Est than the SA and SH groups; the BH group had 
significantly higher Cst and lower Est than the BA group. SA, saline administration and air inhalation, n = 6; SH, saline administration and hydrogen 
inhalation, n = 6; BA, bleomycin administration and air inhalation, n = 11; BH, bleomycin administration and hydrogen inhalation, n = 11. NS, not 
significant; *, p < 0.05; **, p < 0.01; error bars indicate 95% CI
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lungs from mice in the BA and BH groups (p = 0.13) 
(Fig. 5d).
The mRNA expression of fibrinogen and COL1, com-
ponents of the extracellular matrix, were also investigated 
7 days after bleomycin treatment. The levels of fibrinogen 
mRNA were reduced by hydrogen therapy, while the lev-
els of COL1 mRNA were not (Fig. 5e, f ).
Hydrogen inhalation for 7 days suppresses 
the expression of TGF‑β in the alveolar interstitium 
after bleomycin‑induced lung injury
When TGF-β1 protein expression was analyzed by West-
ern blotting, hydrogen treatment did not affect TGF-β1 
expression (Fig.  6a, Additional file  3). However, when 
the localization of TGF-β1 was examined using immu-
nostaining, fewer TGF-β1-positive cells were found in 
the alveolar interstitium after hydrogen therapy than in 
sham/air treated controls (Fig.  6b). Immunostaining for 
IL-6 demonstrated that majority of IL-6-producing cells 
in the lung were alveolar macrophages (Fig. 6c).
Hydrogen inhalation for 7 days reduced the expression 
of IL‑6 in cells in the BALF
Hydrogen inhalation did not alter the number of cells 
in the BALF (BA 969 cells/μL [95% CI 776–1163] vs. 
BH 1017 cells/μL [95% CI 843–1190], p = 0.74) (Fig. 7a). 
Hydrogen inhalation also did not reduce the protein 
concentration in the BALF after bleomycin insult (BA 
2567  μg/mL [95% CI 2304–2830] vs. BH 2258  μg/mL 
[95% CI 2047–2469], p = 0.09) (Fig. 7b).
Real-time RT-PCR using the cells isolated from BALF 
revealed upregulation of IL-6 mRNA 7  days after bleo-
mycin insult. Hydrogen inhalation attenuated this IL-6 
upregulation (Fig. 7c).
Hydrogen inhalation for 7 days reduces M2‑biased 
macrophages in the alveolar interstitium 
after bleomycin‑induced lung injury
To identify the phenotype of macrophages in the alveoli 
and alveolar interstitum, anti-Iba-1 antibody was used 
to detect all macrophages, and anti-CD163 antibody 
Fig. 2 Volumetry evaluated using computed tomography. a Left column. CT images of the thoracic cavity at the level of the left ventricle. Right 
column. Representative images obtained using "Analyze Particles" program. The "Bare Outline" is indicated by the black line. The area of the aerated 
field, that enclosed within the black lines, was analyzed with ImageJ. b The aerated volume was calculated by integrating the aerated area. The 
aerated volume was reduced by bleomycin-induced lung injury, and inhaling hydrogen preserved the aerated volume after bleomycin-induced 
injury. SA, saline administration and air inhalation, n = 6; SH, saline administration and hydrogen inhalation, n = 6; BA, bleomycin administration and 
air inhalation, n = 9, BH, bleomycin administration and hydrogen inhalation, n = 9. NS, not significant; *p < 0.05, **p < 0.01. Error bars: 95% CI
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was used to specifically detect M2-biased macrophages. 
There was an increase in the number of Iba-1-positive, 
CD163-negative macrophages in the alveoli of the lung 
7 days after bleomycin insult, but hydrogen treatment did 
not alter the number of Iba-1-positive, CD163-negative 
cells present (BA 13.0% [95% CI 9.3–16.8%] vs. BH 11.5% 
[95% CI 7.8–15.1%], p = 0.74) (Fig. 8a, b). In contrast, ble-
omycin-induced lung injury increased of the number of 
Fig. 3 Examination of alveolar fibrosis in lung tissue. a Representative images of bleomycin-induced alternations in the alveolar interstitum and 
bronchial epithelium are shown using hematoxylin and eosin (HE) staining (×12.5 and ×200 images) and Elastica Masson (E-M) staining (×200 
image). Extracellular matrix component proteins appear as blue–purple in E-M staining. Red arrows indicated particularly thick collagen bundles, 
which stain as black-purple bundles. Inhalation of hydrogen gas suppressed fibrous tissue production after lung injury. b Lung injury scores were 
low overall and not significantly different between treatment groups. c Ashcroft scores clearly demonstrated that there were more fibrotic changes 
in the lungs of the BA group as compared with the BH group. SA, saline administration and air inhalation, n = 6; SH, saline administration and 
hydrogen inhalation, n = 6; BA, bleomycin administration and air inhalation, n = 11, BH, bleomycin administration and hydrogen inhalation, n = 11. 
*p < 0.05; error bars indicate 95% CI
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Iba-1-positive, CD163-positive macrophages in the alve-
oli, indicating that more M2-biased macrophages were 
present in the tissue, and hydrogen therapy significantly 
decreased the presence of these M2-biased macrophages 
in the alveoli (BA 3.1% [95% CI 1.6–4.5%] vs. BH 1.1% 
[95% CI 0.3–1.8%], p = 0.008) (Fig. 8a, c).
Discussion
Hydrogen inhalation therapy has been proven effective in 
mitigating in several animal models of lung injury includ-
ing hyperoxic lung injury, hemorrhagic shock-induced 
lung injury, radiation-induced lung injury, and bronchial 
asthma [7, 8, 20, 21]. Our study is the first to prove that 
hydrogen inhalation therapy effectively attenuates the 
decline of respiratory physiological function induced by 
bleomycin in a mouse model of persistent lung inflam-
mation and fibrosis. To the best of our knowledge, this is 
the first study to assess the effects of hydrogen inhalation 
using physiologic respiratory function tests and CT volu-
metry. We also demonstrated that the protective effects 
of hydrogen gas inhalation therapy in this lung injury 
model were accompanied by attenuation of pro-inflam-
matory cytokine expression and reduced the number of 
M2-biased macrophages in the lung after bleomycin-
induced lung injury).
In this study, we administered an air mixture with 3.2% 
hydrogen for 6 h daily beginning on the day of bleomycin 
administration and continuing for 21 days. Other inves-
tigations of inhaled hydrogen therapy have shown effec-
tive results with hydrogen concentrations of 2–4% [5, 7, 
20–24], and repeated inhalation was reported to be more 
effective than continuous inhalation in rat model of Par-
kinson’s disease [25]. Because the endpoint of this study 
was to assess lung function during the fibrotic phase 
after lung injury, we targeted treatment during the pro-
liferative phase of ARDS, which ordinary occurs 7 to 
21  days after the onset of lung injury [1]. Our prelimi-
nary studies indicated that the bleomycin-induced lung 
injury model mimicked the temporal changes in pathol-
ogy observed during ARDS and dictated our protocol of 
repeated hydrogen inhalation for 21 days after bleomycin 
administration.
During ARDS, pathogen-associated molecular pat-
tern molecules and damage-associated molecular pat-
tern molecules stimulate type II alveolar epithelial cells 
and alveolar macrophages to secrete pro-inflammatory 
cytokines. The permeability of pulmonary capillaries 
and alveolar epithelial cells increases, and exudate flows 
from the blood vessels into the alveoli and interstitium. 
The immune cells responsible for this are classically acti-
vated macrophages (M1 macrophages) and neutrophils 
Fig. 4 Western blot evaluation of extracellular matrix component proteins. a Western blot evaluation of fibronectin, type 1 collagen (COL1), 
alpha-smooth muscle actin (αSMA) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The original, full-length blot images are shown in 
Supplementary Information. b The band intensity of fibronectin evaluated as a ratio to GAPDH. Inhaling hydrogen gas may decrease the production 
of fibronectin in lung (p = 0.069). SA, saline administration and air inhalation, n = 6; SH, saline administration and hydrogen inhalation, n = 6; BA, 
bleomycin administration and air inhalation, n = 11, BH, bleomycin administration and hydrogen inhalation, n = 11. NS: not significant, **p < 0.01. 
Error bars: 95% CI
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[1]. IL-6, which is expressed in type II alveolar epithe-
lial cells and M1 macrophages, is associated with lung 
fibrosis through the polarization of M2 macrophages 
[26–30]. Although M2 macrophages are important for 
tissue repair, an excess of M2 macrophages can cause 
organ fibrosis [31, 32]. Suppression or deletion of IL-6 
suppresses M2 macrophage polarization and attenu-
ates lung fibrosis [33, 34]. In our study, immunostaining 
Fig. 5 mRNA expression levels of a interleukin (IL)-6, b IL-4, c IL-13, d IL-10, e fibronectin and f type 1 collagen (COL1) were measured using SYBR 
Green 2-step real-time reverse transcriptase polymerase chain reaction (RT-PCR). Inhaling hydrogen gas significantly suppressed the expression of 
IL-6, IL-4, and IL-13 induced by bleomycin administration. The expression of fibronectin is significantly reduced by hydrogen inhalation. SA, saline 
administration and air inhalation, n = 12; SH, saline administration and hydrogen inhalation, n = 12; BA, bleomycin administration and air inhalation, 
n = 28, BH, bleomycin administration and hydrogen inhalation, n = 28. NS: not significant, *p < 0.05, **p < 0.01. Error bars: 95% CI
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Fig. 6 TGF-β1 expression. a TGF-β1 protein in the lung as examined by western blotting. Beta-actin was evaluated as a housekeeping protein. There 
are two TGF-β1 bands, 44 kDa and 13 kDa. The 13 kDa band represents active form. There was no difference of 13 kDa band intensity among the 4 
groups. The original, full-length blot images are shown in Supplementary Information. b Immunostaining for TGF-β1 to localize protein expression 
in the alveoli. Black arrows indicate cells strongly positive for TGF-β1. SA, saline administration and air inhalation; SH, saline administration and 
hydrogen inhalation; BA, bleomycin administration and air inhalation; BH, bleomycin administration and hydrogen inhalation. c Immunostaining 
with IL-6 antibody was performed on lung sections obtained from mice on day 7 after bleomycin administration. Black and white arrows indicate 
alveolar macrophages in BA and BH groups respectively
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showed the expression of IL-6 was induced in alveolar 
macrophages by bleomycin administration. Although 
it is difficult to differentiate between the IL-6 produced 
by the cells and that bound to cells, IL-6 was most likely 
secreted by alveolar cells considering upregulation of 
IL-6 in BALF cells. Our finding that hydrogen inhala-
tion therapy reduced IL-6 mRNA expression is consistent 
with published work demonstrating that hydrogen sup-
presses the expression of IL-6 [7, 20, 35–41]. Therefore, 
it is reasonable to speculate that the reduction in IL-6 
expression in response to hydrogen inhalation therapy 
caused less M2-biased macrophage polarization and less 
fibrosis after bleomycin-induced lung injury.
IL-4 and IL-13 also induce the polarization of mac-
rophages to M2 macrophages, which decreases inflam-
mation and encourages tissue repair. Persistent or 
excessive expression of IL-4 or IL-13 and the accompany-
ing M2 macrophage polarization leads to abnormal organ 
fibrosis [31, 32]. In our study, the expression of IL-4 and 
IL-13 mRNAs were decreased by hydrogen inhalation 
therapy. The regulation of IL-4 and IL-13 by hydrogen 
may result in an anti-fibrotic effect through suppression 
of M2-biased macrophage polarization and thereby 
reduce alveolar fibrosis. TGF-β is secreted from M2 
macrophages [42]. Hydrogen administration decreased 
the number of TGF-β-positive cells in the alveolar inter-
stitium, again indicating that control of M2-biased mac-
rophage polarization may be an important mechanism 
underlying the therapeutic benefits of inhaled hydrogen. 
However, as another interpretation, the decrease in TGF-
β1 positive cells by immunostaining could also be the 
result of downregulation of TGF-β1 production in mes-
enchymal cells and/or epithelial cells by hydrogen gas 
inhalation, reflected in the decrease in TGF-β1 binding 
to TGF-β1 receptors on macrophages in the interstitum. 
The results of this study support models put forth by oth-
ers that hydrogen therapy regulates upstream signals in 
a cascade impacting macrophages and innate immunity 
that leads to inflammation [7, 8, 10, 43].
The study has some limitations. The pathogenesis of 
lung injury in clinical practice is diverse. Bleomycin-
induced lung injury is only one type of drug-induced 
lung injury and does not replicate all possible lung injury 
presentations. Second, determining the most effective 
Fig. 7 Bronchoalveolar lavage fluid (BALF) assay. a Inhaled hydrogen therapy did not affect the number of cells in the BALF. b Hydrogen therapy 
tended to decrease the protein concentration in the BALF (p = 0.09). SA, saline administration and air inhalation, n = 6; SH, saline administration and 
hydrogen inhalation, n = 6; BA, bleomycin administration and air inhalation, n = 15, BH, bleomycin administration and hydrogen inhalation, n = 15. 
NS, not significant; Error bars: 95% CI. c mRNA expression levels of IL-6 in isolated cells from BALF. The median values of IL-6/RPL4 mRNA tended 
to be higher in the BA group as compared with the BH group (p = 0.07). BA, bleomycin administration and air inhalation, n = 10, BH, bleomycin 
administration and hydrogen inhalation, n = 10. Error bars: 95% CI
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hydrogen administration regimen—timing, duration and 
concentration—will be required for clinical application. 
Third, to identify M2-biased macrophages by immu-
nostaining, we used anti-CD163 antibody, although the 
expression of CD163 antigen does not necessarily associ-
ate with the entire cellular phenotype of M2 macrophage 
[44]. Finally, the mechanisms by which hydrogen inhib-
its bleomycin-induced lung injury were not fully elu-
cidated in this study. Hydrogen reduced the number 
of M2-biased macrophages in the alveolar interstitium 
with associated inhibition of increases in IL-6, IL-4 and 
IL-13 that occur after lung injury. Although we observed 
Fig. 8 Immunofluorescent localization of macrophage markers. a Anti-Iba-1 was used to detect total macrophages, and anti-CD163 was used 
to detect M2-biased macrophages. Representative images showing DAPI (blue), Iba-1 (Green, AlexaFlour488), and CD 163 (red, AlexaFlour594). b 
Quantitation of Iba-1-positive, CD163-negative cells (all macrophages except M2 macrophages). c Quantitation of Iba-1-positive, CD163-positive 
cells (M2-biased macrophages). The graphs show the percentage obtained by dividing the number of macrophages of the target phenotype by 
the total number of cells (measured by DAPI staining). There was no difference in the number of Iba-1-positive and CD163-negative cells between 
the groups with and without hydrogen inhalation; however, the number of Iba-1-positive and CD163-positive cells was significantly reduced 
by inhaling hydrogen for 7 days. SA, saline administration and air inhalation, n = 6; SH, saline administration and hydrogen inhalation, n = 6; BA, 
bleomycin administration and air inhalation, n = 15, BH, bleomycin administration and hydrogen inhalation, n = 15. NS: not significant, *p < 0.05, 
**p < 0.01. Error bars: 95% CI
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a convincing impact on M2-biased macrophages in 
response to hydrogen, currently, we do not have clear 
evidence that hydrogen directly affects macrophage 
polarization or fibrotic potential. Moreover, the classifi-
cation of polarized macrophages is rather complex, and 
M2 macrophages are divided into subclasses. A study to 
determine the effects of hydrogen on macrophage polari-
zation, fibrotic potential, or M2 macrophage subclass as 
a potential underlying mechanism of hydrogen therapy is 
warranted and may advance our understanding of hydro-
gen biology.
Conclusion
Repeated hydrogen inhalation therapy with 3.2% hydro-
gen for 6 h per day for 21 days inhibited the decline of res-
piratory physiological function and increase in alveolar 
fibrosis induced by bleomycin. Hydrogen administration 
increased ventilation and increased alveolar compliance, 
which strongly suggests that hydrogen inhalation would 
improve the clinical profile of ARDS patients when used 
as therapy.
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